381 related articles for article (PubMed ID: 21429352)
1. [Expression and clinicopathologic significance of GPC3 and other antibodies in well-differentiated hepatocellular carcinoma].
DU JL; Wei LX; Wang YL
Zhonghua Bing Li Xue Za Zhi; 2011 Jan; 40(1):11-6. PubMed ID: 21429352
[TBL] [Abstract][Full Text] [Related]
2. Distinction of hepatocellular carcinoma from benign hepatic mimickers using Glypican-3 and CD34 immunohistochemistry.
Coston WM; Loera S; Lau SK; Ishizawa S; Jiang Z; Wu CL; Yen Y; Weiss LM; Chu PG
Am J Surg Pathol; 2008 Mar; 32(3):433-44. PubMed ID: 18300806
[TBL] [Abstract][Full Text] [Related]
3. Glypican-3 as a useful diagnostic marker that distinguishes hepatocellular carcinoma from benign hepatocellular mass lesions.
Wang HL; Anatelli F; Zhai QJ; Adley B; Chuang ST; Yang XJ
Arch Pathol Lab Med; 2008 Nov; 132(11):1723-8. PubMed ID: 18976006
[TBL] [Abstract][Full Text] [Related]
4. [Expression of glypican-3, hepatocyte antigen, alpha-fetoprotein, CD34 and CD10 in hepatocellular carcinoma: a clinicopathologic analysis of 375 cases].
Du JL; Wang YL; Shi HY; Guo AT; Wei LX
Zhonghua Bing Li Xue Za Zhi; 2012 May; 41(5):309-13. PubMed ID: 22883669
[TBL] [Abstract][Full Text] [Related]
5. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
Li J; Wei L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
[TBL] [Abstract][Full Text] [Related]
6. Glypican-3 expression distinguishes small hepatocellular carcinomas from cirrhosis, dysplastic nodules, and focal nodular hyperplasia-like nodules.
Libbrecht L; Severi T; Cassiman D; Vander Borght S; Pirenne J; Nevens F; Verslype C; van Pelt J; Roskams T
Am J Surg Pathol; 2006 Nov; 30(11):1405-11. PubMed ID: 17063081
[TBL] [Abstract][Full Text] [Related]
7. [Dysplastic nodule of liver versus early hepatocellular carcinoma: a clinicopathologic and prognostic study].
Chen L; Tan Y; Zeng H; Hou Y; Xu J; Zhao J; Ji Y
Zhonghua Bing Li Xue Za Zhi; 2014 May; 43(5):301-6. PubMed ID: 25030861
[TBL] [Abstract][Full Text] [Related]
8. Immunohistochemistry in the Diagnosis of Hepatocellular Carcinoma.
Choi WT; Kakar S
Gastroenterol Clin North Am; 2017 Jun; 46(2):311-325. PubMed ID: 28506367
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis of well-differentiated hepatocellular lesions: role of immunohistochemistry and other ancillary techniques.
Shafizadeh N; Kakar S
Adv Anat Pathol; 2011 Nov; 18(6):438-45. PubMed ID: 21993269
[TBL] [Abstract][Full Text] [Related]
10. [Study on the morphological features, pathologic diagnosis and differential diagnosis of well-differentiated hepatocellular carcinoma].
Wei L; Du J; Wang Y; Shi H; Zhao J
Zhonghua Bing Li Xue Za Zhi; 2014 Jul; 43(7):459-62. PubMed ID: 25327795
[TBL] [Abstract][Full Text] [Related]
11. Immunohistochemical characteristics of hepatocellular carcinoma in non-cirrhotic livers.
Witjes CD; ten Kate FJ; Verhoef C; de Man RA; IJzermans JN
J Clin Pathol; 2013 Aug; 66(8):687-91. PubMed ID: 23585667
[TBL] [Abstract][Full Text] [Related]
12. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm.
Wang F; Jing X; Wang T; Li G; Li T; Zhang Q; Huang Y; Li J; Wang Y; Gao Y; Han T; Du Z
Am J Clin Pathol; 2012 Jun; 137(6):937-45. PubMed ID: 22586053
[TBL] [Abstract][Full Text] [Related]
13. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
[TBL] [Abstract][Full Text] [Related]
14. Utility of CD34 reactivity in evaluating focal nodular hepatocellular lesions sampled by fine needle aspiration biopsy.
Kong CS; Appenzeller M; Ferrell LD
Acta Cytol; 2000; 44(2):218-22. PubMed ID: 10740609
[TBL] [Abstract][Full Text] [Related]
15. [Significance of glypican-3 mRNA expression in hepatocellular carcinoma tissues and peripheral blood cells].
Li BD; Zhao QC; Zhu YT; Zhang FQ; Dou KF
Zhonghua Wai Ke Za Zhi; 2006 Apr; 44(7):458-62. PubMed ID: 16772080
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic value of glypican-3 in serum and liver for primary hepatocellular carcinoma.
Liu H; Li P; Zhai Y; Qu CF; Zhang LJ; Tan YF; Li N; Ding HG
World J Gastroenterol; 2010 Sep; 16(35):4410-5. PubMed ID: 20845507
[TBL] [Abstract][Full Text] [Related]
17. Significance of Glypican-3 (GPC3) Expression in Hepatocellular Cancer Diagnosis.
Sun B; Huang Z; Wang B; Yu Y; Lin S; Luo L; Wang Y; Huang Z
Med Sci Monit; 2017 Feb; 23():850-855. PubMed ID: 28207681
[TBL] [Abstract][Full Text] [Related]
18. Utilization of spectrins βI and βIII in diagnosis of hepatocellular carcinoma.
Hu S; Jue D; Albanese J; Wang Y; Liu Q
Ann Diagn Pathol; 2019 Apr; 39():86-91. PubMed ID: 30798076
[TBL] [Abstract][Full Text] [Related]
19. SUOX is a promising diagnostic and prognostic biomarker for hepatocellular carcinoma.
Jin GZ; Yu WL; Dong H; Zhou WP; Gu YJ; Yu H; Yu H; Lu XY; Xian ZH; Liu YK; Cong WM; Wu MC
J Hepatol; 2013 Sep; 59(3):510-7. PubMed ID: 23665285
[TBL] [Abstract][Full Text] [Related]
20. CD34, PCNA and CK19 expressions in AFP- hepatocellular carcinoma.
Cui DJ; Wu Y; Wen DH
Eur Rev Med Pharmacol Sci; 2018 Aug; 22(16):5200-5205. PubMed ID: 30178842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]